Biotech Winners And Losers Out Of ASH
A slew of biotech companies studying blood disease treatments presented data this past weekend at the annual American Society of Hematology (ASH) meeting – and,…
A slew of biotech companies studying blood disease treatments presented data this past weekend at the annual American Society of Hematology (ASH) meeting – and,…
Companies involved in spectroscopy, bioelectronic medicine and telemedicine make up the three new biotech stocks to watch highlighted in today’s article, which also highlights new…
While President Trump still refuses to concede and control of the Senate is still technically to be determined, a Biden presidency come January 20th appears…
From traditional “Big Pharma” stocks that have adopted (or are adopting) a greater focus on biotech to large “pure-play” biotech companies to “emerging” biotech stocks…
The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors…
Amid a third-quarter earnings season that has been a mixed bag of beats and misses for drug/biotech companies, today’s article highlights five drug/biotech stocks that…
When it comes to the biotech stock that’s the focus of today’s article, which plummeted in mid-October when the company abruptly pulled the plug on…
October has seen the FDA approve the first drug for COVID-19 (remdesivir), the first treatment for Ebola virus (Regeneron Pharmaceuticals’ Inmazeb), and the first drug…
When it comes to the seven “unhealthy” biotech stocks that are the focus of today’s article, the author advises the following: “While these aren’t terrible…
Amid setbacks for various potential COVID-19 vaccines and treatments, election risk, strengthening M&A activity, and more, what’s the outlook for healthcare and biotech in the…